NexCalibur Therapeutics
NexCalibur Therapeutics is a pre-clinical stage biotechnology company focused on developing personalized therapies and preventative vaccines for solid tumor cancers. Their innovative NexNeo platform utilizes artificial intelligence and engineered antigen-presenting cells to identify and validate neoantigens, creating tailored therapies for patients. The platform has shown promising results in preclinical trials, including a hybrid phase I/II clinical trial for metastatic colorectal cancer. Additionally, NexCalibur aims to design off-the-shelf preventive vaccines for high-risk individuals, potentially revolutionizing cancer prevention and treatment.
NexCalibur Therapeutics
NexCalibur Therapeutics is a pre-clinical stage biotechnology company focused on developing personalized therapies and preventative vaccines for solid tumor cancers. Their innovative NexNeo platform utilizes artificial intelligence and engineered antigen-presenting cells to identify and validate neoantigens, creating tailored therapies for patients. The platform has shown promising results in preclinical trials, including a hybrid phase I/II clinical trial for metastatic colorectal cancer. Additionally, NexCalibur aims to design off-the-shelf preventive vaccines for high-risk individuals, potentially revolutionizing cancer prevention and treatment.